• 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
  • 2
    Van Cutsem E, Peeters M, Siena S, et al. Open-label, phase 3 clinical trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25: 1658-1664.
  • 3
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
  • 4
    Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 1201-1208.
  • 5
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
  • 6
    Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041-1047.
  • 7
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
  • 8
    Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer. 1999; 35: 1343-1347.
  • 9
    Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999; 17: 3560-3568.
  • 10
    Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004; 58: 984-990.
  • 11
    Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. 2007; 25: 1134-1143.
  • 12
    Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008; 19: 92-98.
  • 13
    Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6: 803-812.
  • 14
    Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005; 23: 5235-5246.
  • 15
    Gullick WJ, Hughes CM, Mellon K, Neal DE, Lemoine NR. Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol. 1991; 164: 285-289.
  • 16
    Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37( suppl 4): S9-S15.
  • 17
    Van Cutsem E, Peeters M, Gelderblom H, et al. Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST). Ann Oncol. 2007; 18S( suppl vii): 22. Abstract O-0034.
  • 18
    Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-1634.
  • 19
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19: 210-216.
  • 20
    Mathias S, Pritchard ML, Colwell HH, Lu J, Wright N. What is the minimal clinically important difference and responsiveness of a patient-reported outcome questionnaire for metastatic colorectal cancer? Ann Oncol. 2006; 17( suppl 9). Abstract 349P.
  • 21
    Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest. 2003; 21: 526-535.
  • 22
    Walters SJ, Brazier JE. Comparison of the minimally important difference for 2 health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005; 14: 1523-1532.
  • 23
    Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. New York, NY: Springer; 2003.
  • 24
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-376.
  • 25
    Fairclough DL. Design and analysis of quality of life studies in clinical trials. Interdisciplinary statistics. Boca Raton, FL: Chapman & Hall/CRC; 2002.
  • 26
    Fielding S, Fayers PM, Loge JH, Jordhoy MS, Kaasa S. Methods for handling missing data in palliative care research. Palliat Med. 2006; 20: 791-798.
  • 27
    Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007; 97: 1469-1474.
  • 28
    Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007; 25: 3230-3237.
  • 29
    Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007; 25: 3238-3245.